BioQ Pharma and Lunatus add a third infusion pharmaceutical to existing Commercial Agreement covering Arabian Gulf and Middle East

April 4th, 2017

BioQ Pharma Incorporated, a specialty pharmaceutical company, and Lunatus, a company focused on building and developing profitable pharmaceutical brands in the Arabian Gulf and Middle East markets, have announced the addition of a third, ready-to-use, infusible pharmaceutical product to their existing strategic distribution, supply, and commercial agreement.

Adding this third drug expands BioQ Pharma and Lunatus’ previously signed agreement, covering ropivacaine and propofol infusion pharmaceutical products in Saudi Arabia, the United Arab Emirates, Qatar, and Kuwait.

Link to full press release here: and-Lunatus-Add-a-Third-Infusion-Pharmaceutical-to-Commercial-Agreement-Covering-Arabian-Gulf-Area- and-Middle-East.html

← Previous Post Next Post →